The biotechnology sector is bound to be one of the most profitable and most progressive industries in the next few decades. The volatility of an unpopular presidential administration, coupled with the release of verbal hostilities with an Asian dictatorship that can literally launch World War III, puts the global market uncertainty at a high.
Yet, the biotech industry continues to attract investment. While riskier tech ventures like space tourism and cryptocurrency caution the more conservative financiers to hold on to their precious monies, the opposite goes for biotech — the more radical and revolutionary the technique or product is, the more redemptive it is hailed.
That mission and vision to enhance the health and lifestyle of the people who battle each day against a blighted environment, disease, aging, and death are what propels biotechnology above the rest of the industries. As described by Bio, technological innovations continue to harness natural elements such as human and animal cells, genomes, the soil, the wind, and water to formulate medicine and procedures that can arrest debilitating or lethal illnesses.
Farmers have used biotechnology to increase the yield of their crops and free their harvest of toxins and other damaging allergens. Medical research centers leverage on it to arrest the outbreak of diseases before it happens and combat life-crippling illnesses such as cancer and cellular degeneration, just to name a few. Diseases that have been previously regarded as “untreatable” can now be countered by more than 250 biotech products and services generally available to the public.
The market continues to grow as more players come in. As reported by Statista, about 670 biotech companies were thriving in the U.S., with a market capitalization of $890 billion and a yearly revenue of more than $130 billion.
The Markets Insider further forecasts that biotech will surpass almost all other industries in 2017, fueled by rising concerns of both the government and the public about seemingly insoluble health problems, like medical conditions which continue to exact a heavy toll on the economy and public health alike. Examples would be cardiovascular diseases including strokes and heart attacks.
All these then place biotech company Hemogenyx LLC’s (LON:HEMO) breakthrough products for leukemia and other severe blood diseases at the cutting-edge of the biotechnology field. It is a must-watch for investors who want to save millions of lives.
The timing and its own unique selling proposition have positioned Hemogenyx on the radar of investors, venture capitalists, and biotech industry leaders. The biotech startup aims to revolutionize the treatment of blood diseases. In doing so, it has honed its considerable resources and teams of medical researchers and scientists into providing a breakthrough treatment for leukemia patients and others afflicted with other cancerous blood diseases.
Leukemia happens when cancerous white blood cells increase without restriction and, against all resistance, block the healthy distribution of blood into other parts of the body. The patient’s immune system takes a terrible blow, as they suffer a variety of medical conditions such as night sweats, nausea, fevers with chills, anemia, and constant fatigue.
The uniqueness of Hemogenyx’s treatment lies in its goal of regenerating the bloodstream of the patient. First, it can be done through CDX antibodies. According to Dr. Vladislav Sandler, CEO, and founder of Hemogenyx, “The unique antibodies redirect immune cells of the patients to eliminate and attack blood stem cells of the same patient. This type of antibody will hopefully eliminate chemotherapy and radiation and solve the problem of non-specific toxicity of these treatments.”
For patients needing a bone marrow or blood stem cells transplant, the second treatment uses Hu-PHEC or postnatal hemogenic endothelial cells. These cells are removed from the patient’s own liver or umbilical cord and placenta. Hemogenyx can then isolate, purify and reprogram them to become the blood stem cells that will be transplanted back to the patient. There is very little risk in the procedure as the cells are immediately compatible with the patient — after all, the patient is the donor.
Incompatibility between a donated organ and the patient receiving it is one reason why bone marrow transplant, the usual treatment given to leukemia patients, fail. About 50 percent of these patients who had undergone a successful operation in this area report a breakdown or organ malfunction weeks or months after. Another obstacle to bone marrow transplant is finding a suitable donor in the first place; only 60 percent of patients on a hospital list have a good chance of securing one.
Hemogenyx has gotten its own needed shot in the arm when it was acquired by investor Silver Falcon this year. According to Digital Look, the “reverse takeover” reached a value of £8 million. Silver Falcon issued more than 228 million shares at a value of 3.5 pence each. Silver Falcon changed its name and control at its AGM last October 4th to Hemogenyx and started trading on October 5th, under the new symbol, LON:HEMO.
The relief that Hemogenyx could provide to more than the one million leukemia patients worldwide is a 180-degree turn from the standard medical response to an operation. If you want to have a clear idea of what it means, think of the patient’s bloodstream, once weak and dying, suddenly being rejuvenated, almost by magic, to give him power and new life.
Create your free account to unlock your custom reading experience.